News 06.03.2024 Lisbon, Portugal - 06.03.2024 Neurimmune announced today that a Donald L. Price Memorial Lecture will be held at the 18th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, AD/PD 2024, in Lisbon, Portugal and virtually from March 5 to March 9, 2024. Professor Michel Goedert, Program Leader at the...
News 28.02.2024 (BOSTON: February 27, 2024) – Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is awarding US$2.2 million to LimmaTech Biologics AG to advance the development of its novel vaccine candidate targeted to prevent Neisseria gonorrhoeae infections. LimmaTech is a Swiss clinical stage biotech company that has built a robust pipeline of innovative vaccines to...
News 22.02.2024 SCHLIEREN, Switzerland--(BUSINESS WIRE)--LimmaTech Biologics AG announced positive interim data from its Phase I/II clinical trial evaluating Shigella4V (S4V), a tetravalent bioconjugate vaccine candidate against shigellosis, an infectious disease caused by Shigella bacteria. Shigellosis is a serious infection and remains the second leading cause of fatal diarrheal disease, particularly in infants...
News 14.02.2024 Switzerland, 14 February 2024 – CUTISS AG, a Swiss clinical-stage life science company focused on skin regenerative medicine and tissue engineering, has announced positive one-year follow-up data from its Phase 2 clinical trial of the lead product denovoSkin™, in adult and adolescent severe burn patients. Following the announced positive primary endpoint in Q1...
News 06.02.2024 Schlieren / Zurich, Switzerland, February 5, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies for viral infections and oncology, announced today that it has strengthened its senior team with the appointments of Kristie B. Clemmer and Dr. Maartje Verschuur as VP Clinical Operations and...